Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) CEO Vimal Mehta sold 30,000 shares of the stock in a transaction on Friday, December 16th. The stock was sold at an average price of $19.44, for a total transaction of $583,200.00. Following the completion of the sale, the chief executive officer now owns 9,957 shares in the company, valued at approximately $193,564.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
BioXcel Therapeutics Price Performance
BTAI traded down $0.05 during midday trading on Monday, hitting $20.00. 287,137 shares of the company traded hands, compared to its average volume of 454,671. The company has a current ratio of 10.34, a quick ratio of 10.28 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $560.44 million, a price-to-earnings ratio of -4.10 and a beta of 1.30. BioXcel Therapeutics, Inc. has a 52-week low of $8.80 and a 52-week high of $24.57. The business has a 50 day simple moving average of $14.34 and a two-hundred day simple moving average of $13.85.
BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) last posted its quarterly earnings results on Thursday, November 10th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.15). The firm had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $3.05 million. On average, equities analysts forecast that BioXcel Therapeutics, Inc. will post -5.31 earnings per share for the current fiscal year.
Hedge Funds Weigh In On BioXcel Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the business. Point72 Hong Kong Ltd purchased a new position in shares of BioXcel Therapeutics in the second quarter worth about $50,000. Quantbot Technologies LP acquired a new stake in BioXcel Therapeutics during the third quarter worth about $57,000. Amalgamated Bank acquired a new stake in BioXcel Therapeutics during the first quarter worth about $59,000. Game Plan Financial Advisors LLC acquired a new stake in BioXcel Therapeutics during the second quarter worth about $142,000. Finally, Virtus ETF Advisers LLC increased its position in BioXcel Therapeutics by 46.3% during the second quarter. Virtus ETF Advisers LLC now owns 11,284 shares of the company’s stock worth $149,000 after purchasing an additional 3,571 shares during the last quarter. 45.32% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of research firms have recently weighed in on BTAI. Canaccord Genuity Group increased their price objective on shares of BioXcel Therapeutics from $75.00 to $76.00 and gave the stock a “buy” rating in a research note on Friday, November 11th. Guggenheim cut their price objective on shares of BioXcel Therapeutics from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, November 11th. The Goldman Sachs Group upgraded shares of BioXcel Therapeutics from a “sell” rating to a “neutral” rating and set a $16.00 price objective on the stock in a research note on Thursday, December 1st. HC Wainwright lowered their price target on shares of BioXcel Therapeutics from $110.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, August 24th. Finally, Canaccord Genuity Group increased their price target on shares of BioXcel Therapeutics from $75.00 to $76.00 and gave the stock a “buy” rating in a report on Friday, November 11th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $53.11.
BioXcel Therapeutics Company Profile
(Get Rating)
BioXcel Therapeutics, Inc is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
Read More
- Get a free copy of the StockNews.com research report on BioXcel Therapeutics (BTAI)
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here’s Why
- Four Profitable RV Stocks To Ride Out Recession
- Can Boeing Stock Soar in 2023?
- How Do Chipmakers Stack Up When It Comes To Growth?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioXcel Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and BioXcel Therapeutics wasn’t on the list.
While BioXcel Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by entering your email address below.
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
